AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01438931
Drug: DA-9501
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine hydrochloride variable dose
Trial: NCT01216046
Drug: VX-809
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, taken once daily
Trial: NCT01216046
Drug: VX-770
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, taken once every 12 hours
Trial: NCT03913104
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.
Trial: NCT01379521
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01379521
Drug: everolimus placebo
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00003057
Drug: loperamide hydrochloride
RxNorm normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003057
Drug: octreotide acetate
RxNorm normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00957671
Drug: Recombinant human growth hormone
RxNorm normalized name: Recombinant human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
Trial: NCT03502694
Drug: Lumicitabine
RxNorm normalized name: Lumicitabine
DrugBank: Lumicitabine (DB14808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive loading dose and maintenance dose of lumicitabine tablets orally.
Trial: NCT00513266
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00513266
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01914965
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
Trial: NCT04659317
Drug: Oxycodone 5 mg Oral Tablet
RxNorm normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed
Trial: NCT00281983
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00281983
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00281983
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00281983
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00796640
Drug: ER Paliperidone
RxNorm normalized name: paliperidone Extended Release Oral Tablet
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00826527
Drug: Solifenacin PO
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab 5 mg Daily for 12 Weeks
Trial: NCT01580735
Drug: ARQ 197
RxNorm normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd
Trial: NCT03142893
Drug: Ketoconazole Pill
RxNorm normalized name: ketoconazole Pill
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole pill is taken 4 times per Inpatient Stay
Trial: NCT03142893
Drug: Ganirelix
RxNorm normalized name: Ganirelix
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganirelix subcutaneous injection is administered twice per Inpatient Stay
Trial: NCT03142893
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone Pills is taken twice per Inpatient Stay
Trial: NCT03142893
Drug: Dexamethasone Injection
RxNorm normalized name: dexamethasone Injection
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone IV injection is given twice per Inpatient Stay
Trial: NCT03142893
Drug: Recombinant Human Luteinizing Hormone
RxNorm normalized name: Recombinant human luteinizing hormone
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
Trial: NCT03142893
Drug: Gonadorelin
RxNorm normalized name: Gonadorelin
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadorelin IV injection is given twice per Inpatient Stay
Trial: NCT03142893
Drug: Corticorelin
RxNorm normalized name: corticorelin
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticorelin IV injection is given twice per Inpatient Stay
Trial: NCT03142893
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay
Trial: NCT02725359
Drug: Tizanidine
RxNorm normalized name: Tizanidine
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group T: 6 mg tizanidine1 hour before surgery
Trial: NCT02725359
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
Trial: NCT02725359
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: USG guided SCPB with saline bilaterally 10 ml each side
Trial: NCT00878605
Drug: Cyclo-Z
RxNorm normalized name: Z-160
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
Trial: NCT03592498
Drug: Sulfadiazine, Silver
DrugBank: Sulfadiazine (DB00359)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of silver sulfadiazine ointment, bandage covered with gauze and bandage.
Trial: NCT00862225
Drug: Desloratadin
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
Trial: NCT04246502
Drug: Capecitabine,Trastuzumab, and Pertuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: as instruction
Trial: NCT04457934
Drug: Plenvu
RxNorm normalized name: Plenvu
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients in both Groups will drink will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy guidelines
Trial: NCT00970424
Drug: Dutogliptin
RxNorm normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dutogliptin, oral tablet administered once daily on background of pioglitazone
Trial: NCT01810783
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
Trial: NCT00583102
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine dosage: 3.0 g/m2 IV over 3 hours every 12 hours on days 3-7.
Trial: NCT00995618
Drug: Tranilast
RxNorm normalized name: Tranilast
DrugBank: Tranilast (DB07615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranilast tablets, 300 mg, QD
Trial: NCT00995618
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat Tablets, 40 mg, QD
Trial: NCT00995618
Drug: Combination - Tranilast and Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tranilast, 300 mg QD; Febuxostat, 40 mg QD
Trial: NCT00002471
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002471
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002471
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002471
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002471
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002471
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002471
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002471
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00428441
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, based on INR levels, according to D-dimer levels
Trial: NCT01504919
Drug: Nicotine Patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-week supply of nicotine patches given to participants ready to quit smoking.
Trial: NCT03395873
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Decitabine 20mg/m2 IV day 1-5, every 28 days~* Avelumab 10mg/kg IV, day 1, every 14 days
Trial: NCT03684278
Drug: Infusion of 5 mg/kg Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
Trial: NCT03684278
Drug: Infusion of 10 mg/kg Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
Trial: NCT01907217
Drug: Methohexitone
RxNorm normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
Trial: NCT01907217
Drug: Suxamethonium
RxNorm normalized name: Suxamethonium
DrugBank: Succinylcholine (DB00202)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
Trial: NCT01248078
Drug: Keflex
RxNorm normalized name: Keflex
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g of i.v. cefazolin singleshot administered before skin incision
Trial: NCT01248078
Drug: Keflex
RxNorm normalized name: Keflex
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g of i.v. cefazolin singleshot administered after umbilical cord clamping
Trial: NCT01074151
Drug: duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: any exposure to duloxetine that occurred during pregnancy
Trial: NCT03121573
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,
Trial: NCT01248078
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100cc administered before skin incision
Trial: NCT00692250
Drug: Colesevelam hydrochloride film-coated tablets (Cholestagel)
RxNorm normalized name: colesevelam
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001436
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04581356
Drug: Voxelotor
RxNorm normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: daily voxelotor 1500mg oral medication
Trial: NCT02411253
Drug: rhIL-2
RxNorm normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
Trial: NCT01037699
Drug: rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002792
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002792
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002792
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02205476
Drug: PF-06473871
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
Trial: NCT02205476
Drug: PF-06473871
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
Trial: NCT00003697
Drug: vadimezan
RxNorm normalized name: Vadimezan
DrugBank: Vadimezan (DB06235)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03708744
Drug: D:zolmitriptan nasal spray
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D: 2.5 mg/0.1 mL intranasal zolmitriptan
Trial: NCT02570971
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02391714
Drug: Povidone-Iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
Trial: NCT02391714
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
Trial: NCT01050699
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
Trial: NCT02724423
Drug: NRL-1
RxNorm normalized name: NRL-1
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02648659
Drug: Ilaprazole
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 10mg 1tablet qid(4 times/day)
Trial: NCT02648659
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500mg 1capsule qid(4times/day)
Trial: NCT02648659
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 250mg 2tablets tid(3times/day)
Trial: NCT01276080
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tablets
Trial: NCT00101062
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02342275
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
Trial: NCT02342275
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
Trial: NCT02485418
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol infusion at 20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes.
Trial: NCT02721420
Drug: dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00725127
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/day upon awakening for five years
Trial: NCT00725127
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/day at bedtime for five years
Trial: NCT02475499
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Trial: NCT02475499
Drug: GLP-1 analogs
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Trial: NCT02475499
Drug: Biguanides
RxNorm normalized name: Biguanides
DrugBank: Biguanide (DB13100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Trial: NCT04609579
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pembrolizumab (KEYTRUDA®) will be administered as an intravenous infusion on Day 8 in Cycle 1 (28-day cycle) and on Day 1 of each 21-day cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs.
Trial: NCT03287947
Drug: nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral nintedanib, taken twice daily
Trial: NCT02536729
Drug: Oral Sodium Phosphate - Normal preparation
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02536729
Drug: Oral sodium phosphate - Modified Preparation
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02536729
Drug: polyethylene glycol + Electrolytes
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02137928
Drug: carboplatin periocular injection
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mg/2ml carboplatin periocular injection together with chemotherapy
Trial: NCT00360971
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.